Drug news
Signifor(Novartis) success in Phase III Cushings Disease trial
Signifor (pasireotide)from Novartis, significantly reduced urinary cortisol levels and improved symptoms of Cushing's disease in the largest clinical study of this endocrine disorder ever conducted. Results of the clinical trial conducted at centers on four continents appear in the March 8 New England Journal of Medicine and show that treatment with pasireotide cut cortisol secretion an average of 50 percent and returned some patient's levels to normal.see N Engl J Med 2012;366:914-24.
-"A 12-Month Phase 3 Study of Pasireotide in Cushing�s Disease"-Annamaria Colao, M.D., Ph.D., Stephan Petersenn, M.D., John Newell-Price, M.D., Ph.D., James W. Findling, M.D., Feng Gu, M.D., Mario Maldonado, M.D., Ulrike Schoenherr, Dipl.-Biol., David Mills, M.Sc.,
Luiz Roberto Salgado, M.D., and Beverly M.K. Biller, M.D., for the Pasireotide B2305 Study Group.